412 related articles for article (PubMed ID: 27545110)
41. Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2 Diabetes, and Nondiabetic Patients.
Ueberberg S; Nauck MA; Uhl W; Montemurro C; Tannapfel A; Clark A; Meier JJ
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32271378
[TBL] [Abstract][Full Text] [Related]
42. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Harja E; Lord J; Skyler JS
Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
[TBL] [Abstract][Full Text] [Related]
43. The patterns of extrainsular endocrine cells in pancreatic cancer.
Schmied BM; Ulrich AB; Friess H; Büchler MW; Pour PM
Teratog Carcinog Mutagen; 2001; 21(1):69-81. PubMed ID: 11135322
[TBL] [Abstract][Full Text] [Related]
44. Lipid Droplet Accumulation in Human Pancreatic Islets Is Dependent On Both Donor Age and Health.
Tong X; Dai C; Walker JT; Nair GG; Kennedy A; Carr RM; Hebrok M; Powers AC; Stein R
Diabetes; 2020 Mar; 69(3):342-354. PubMed ID: 31836690
[TBL] [Abstract][Full Text] [Related]
45. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
46. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
Ahrén B; Foley JE
Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
[TBL] [Abstract][Full Text] [Related]
47. Organisation of the human pancreas in health and in diabetes.
Atkinson MA; Campbell-Thompson M; Kusmartseva I; Kaestner KH
Diabetologia; 2020 Oct; 63(10):1966-1973. PubMed ID: 32894306
[TBL] [Abstract][Full Text] [Related]
48. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
49. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
50. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.
Marchetti P; Lupi R; Bugliani M; Kirkpatrick CL; Sebastiani G; Grieco FA; Del Guerra S; D'Aleo V; Piro S; Marselli L; Boggi U; Filipponi F; Tinti L; Salvini L; Wollheim CB; Purrello F; Dotta F
Diabetologia; 2012 Dec; 55(12):3262-72. PubMed ID: 22965295
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma.
Andea A; Sarkar F; Adsay VN
Mod Pathol; 2003 Oct; 16(10):996-1006. PubMed ID: 14559982
[TBL] [Abstract][Full Text] [Related]
52. Diabetes mellitus is associated with an increased expression of resistin in human pancreatic islet cells.
Al-Salam S; Rashed H; Adeghate E
Islets; 2011; 3(5):246-9. PubMed ID: 21750415
[TBL] [Abstract][Full Text] [Related]
53. [Pax4 transdifferentiates glucagon-secreting alpha cells to insulin-secreting beta endocrine pancreatic cells].
Collombat P; Mansouri A
Med Sci (Paris); 2009; 25(8-9):763-5. PubMed ID: 19765395
[No Abstract] [Full Text] [Related]
54. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
55. Three new drugs for type 2 diabetes.
Drug Ther Bull; 2008 Jul; 46(7):49-52. PubMed ID: 18603639
[TBL] [Abstract][Full Text] [Related]
56. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
Bonner-Weir S; In't Veld PA; Weir GC
Diabetes Obes Metab; 2014 Jul; 16(7):661-6. PubMed ID: 24400596
[TBL] [Abstract][Full Text] [Related]
57. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
58. Impaired islet turnover in human donor pancreata with aging.
Reers C; Erbel S; Esposito I; Schmied B; Büchler MW; Nawroth PP; Ritzel RA
Eur J Endocrinol; 2009 Feb; 160(2):185-91. PubMed ID: 19004984
[TBL] [Abstract][Full Text] [Related]
59. [Therapeutic use and adverse events of incretin-related drugs].
Ishikawa M; Yamada Y
Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
[No Abstract] [Full Text] [Related]
60. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
